SOPHiA GENETICS enables institutions across
the globe to launch world-class oncology testing
BOSTON, MA and ROLLE,
Switzerland, Feb. 24,
2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq:
SOPH), a pioneer in AI healthcare technology and a leader in
data-driven medicine, announced a new milestone in the global
adoption of its groundbreaking cancer testing applications
MSK-ACCESS® powered with SOPHiA DDM™ and
MSK-IMPACT® powered with SOPHiA DDM™. Thirty-seven
prominent institutions, including top researchers and key opinion
leaders worldwide, have already adopted the recently launched
Liquid Biopsy and Solid Tumor applications.
Professor Umberto Malapelle,
Chair of the Predictive Molecular Pathology Laboratory at the
Department of Public Health of the University Federico II of
Naples, Italy and the Scientific
Secretary of the International Society of Liquid Biopsy, championed
the new applications to support his research on lung and other
cancers.
"When I learned SOPHiA GENETICS was offering applications from
MSK on the SOPHiA DDM™ platform, I was really interested in the
evaluation of the performance of this test, in particular because I
see SOPHiA GENETICS as true collaborators to help pave the way for
the future of cancer research," said Professor Malapelle.
"Bringing best-in-class technology to global organizations is
crucial to help advance better health care for all. We are proud to
work with trailblazers like Professor Malapelle, who are utilizing
our technology and the collective power of our network to make
strides in the next wave of cancer care," said Ross Muken, President, SOPHiA GENETICS.
Of the thirty-seven institutions adopting MSK solutions,
thirty-four have signed on to adopt MSK-ACCESS®
powered with SOPHiA DDM™, just ten months after the Liquid Biopsy
application's launch. The decentralized deployment of
MSK-ACCESS® has enabled hospitals and labs across the
globe to launch world-renowned Liquid Biopsy testing from within
the walls of their own institution, providing patients with a
less-invasive option for genomic testing. In many cases, this
decentralized testing also results in lower costs and faster
turnaround times, while also enabling institutions to retain
control of their patients' data for research or other purposes.
Internationally recognized organizations adopting the
application include: Heidelberg University Hospital in Germany; Biopticka Laboratory in the
Czech Republic; Hospital del Mar
and Hospital La Fe in Spain;
University Hospital of Nice and Marseille Regional Hospital Center
in France; and Jewish General
Hospital in Canada.
The complementary solid tumor application,
MSK-IMPACT® powered with SOPHiA DDM™, has also attracted
significant interest from leading organizations across the globe,
including: the Jiménez Díaz Foundation University Hospital in
Spain; the Cyprus Institute of
Neurology and Genetics in Cyprus;
and Sofiva Genomics in Taiwan.
Memorial Sloan Kettering Cancer Center (MSK) and SOPHiA GENETICS
partnered in 2023 with a vision to use the sophisticated technology
of the SOPHiA DDM™ Platform to bring MSK's state-of-the-art cancer
testing capabilities to precision medicine institutions worldwide.
The two leaders launched the Liquid Biopsy test
MSK-ACCESS® powered with SOPHiA DDM™ in April 2024. In October
2024, SOPHiA GENETICS announced a definitive
partnership agreement with AstraZeneca (LSE/STO/Nasdaq: AZN)
to accelerate the deployment of MSK-ACCESS® powered with
SOPHiA DDM™, aiming to increase the availability of this innovative
Liquid Biopsy solution worldwide. In November 2024, SOPHiA GENETICS announced the
launch of the complementary Solid Tumor test,
MSK-IMPACT® powered with SOPHiA DDM™. These
collaborations have the potential to transform cancer research as
they enable healthcare providers to draw from a continuously
evolving base of real-world data and gain insights from diverse
populations while using best-in-class technology.
Join us on Tuesday, February 25,
2025, at 11:00 a.m. (11:00)
EDT / 5:00 p.m. (17:00) CET for the
Precision Oncology Showcase, a virtual webinar which will spotlight
the transformative potential of decentralized, AI-driven
technologies for the advancement of cancer care.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH)
is a cloud-native healthcare technology company on a mission to
transform patient care by expanding access to data-driven medicine
globally. It is the creator of the SOPHiA DDM™ Platform, which
analyzes complex genomic and multimodal data and generates
real-time, actionable insights for a broad global network of
hospital, laboratory, and biopharma institutions. For more
information, visit SOPHiAGENETICS.com and connect with us on
LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
Memorial Sloan Kettering (MSK)
has institutional financial interests related to SOPHiA
GENETICS.
Forward-Looking Statements
This press
release contains statements that constitute forward-looking
statements. All statements other than statements of historical
facts contained in this press release, including statements
regarding SOPHiA GENETICS future results of operations and
financial position, business strategy, products and technology,
partnerships and collaborations, as well as plans and objectives of
management for future operations, are forward-looking statements.
Forward-looking statements are based on SOPHiA GENETICS'
management's beliefs and assumptions and on information currently
available to the company's management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in the
company's filings with the U.S. Securities and Exchange Commission.
No assurance can be given that such future results will be
achieved. Such forward-looking statements contained in this press
release speak only as of its date. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
the company's expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
Logo -
https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/leading-healthcare-institutions-adopt-msk-access-for-liquid-biopsy-testing-302383210.html
